| Field | Specification |
|---|---|
| Target | |
| Gene symbol | |
| Alternative names | INHBA |
| UniProt # | |
| Species | |
| Applications | |
| Tag | |
| Expression system | |
| Expression region | |
| Molecular weight | |
| Purity | |
| Biological activity | |
| Endotoxin level | |
| Animal origin-free | |
| Reconstitution | |
| Formulation | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Recombinant Human Activin A Protein is a tag-free, disulfide-linked homodimer of the inhibin beta A subunit (gene INHBA), expressed in HEK293 human cells. It is manufactured in an animal-free, xeno-free format and supplied lyophilized without carrier protein, at >95% purity by SDS-PAGE and endotoxin <0.5 EU/µg.
Activin A is commonly used in human iPSC and ESC differentiation protocols, for primitive-streak and mesendoderm induction, definitive endoderm specification and the pancreatic and hepatic programs that follow. Expression in human cells supports mammalian folding and post-translational processing of the dimeric ligand. Each lot is tested for purity, endotoxin and biological activity before release, and the product has been reported in peer-reviewed studies on chemical reprogramming, pluripotent stem-cell culture and directed differentiation.
Expression system: HEK293 human cells · Tag-free · Animal-free
Scientific Background
Activin A belongs to the TGF-β superfamily. It signals through heteromeric receptor complexes made of type II Activin receptors (mainly ACVR2A and ACVR2B) and the type I receptor ALK4 (ACVR1B). Receptor activation leads to phosphorylation of SMAD2 and SMAD3, which associate with SMAD4 and regulate context-dependent transcription in the nucleus.
Activin signaling takes part in embryonic patterning, pluripotency, germ-layer specification, tissue morphogenesis, reproductive biology, inflammation, fibrosis, hematopoiesis and tissue repair. In pluripotent stem-cell work, the lineage that results is shaped by how much Activin A is added and for how long, by the starting cell state and medium, and by crosstalk with WNT, BMP, FGF and PI3K/AKT signaling, so dose and timing need to be optimized for each cell line and target lineage.
Research Applications
Activin A is mainly used in the early stages of directed differentiation of human pluripotent stem cells. The table summarizes where it is typically placed in a workflow; it is a planning guide, not a universal protocol.
| Application | Role of Activin A | Typical stage | Other signals often used |
|---|---|---|---|
| Definitive endoderm | Drives early endodermal programs | Early differentiation, after pluripotent-cell preparation | WNT modulation; FGF/PI3K control depending on the protocol |
| Mesendoderm / primitive streak | Supports early germ-layer and primitive-streak-like transitions | Very early differentiation | WNT activation; BMP or FGF depending on the target lineage |
| Pancreatic differentiation | Establishes definitive endoderm | Upstream of pancreatic progenitor specification | Retinoid signaling, FGF, BMP modulation and pathway-specific small molecules |
| Hepatic differentiation | Supports early definitive-endoderm formation | Before hepatic specification and maturation | BMP, FGF, HGF, OSM and maturation supplements |
| Organoid research | Supports selected early developmental stages | Depends on organoid type and stage | WNT, BMP, FGF, EGF and tissue-specific signals |
| Chemical reprogramming | Supports selected pluripotent-state or reprogramming conditions | Protocol-specific | Defined small-molecule combinations and other growth factors |
| Pluripotent stem-cell culture | Activin/Nodal pathway support in some defined culture systems | Platform-dependent; the requirement varies between systems | Defined basal medium and matrix |
Planning considerations
- Define the stage Activin A is used for (pluripotency support, mesendoderm, definitive endoderm or a later step) and note the basal medium, WNT/BMP/FGF conditions and small molecules used with it.
- Optimize concentration and exposure time for each cell line. Published concentrations vary widely between applications, and exposure beyond the intended window can shift the resulting cell population.
- Key variables include starting-cell quality, seeding density at induction, medium and supplements, matrix or coating, and WNT, FGF, BMP and PI3K/AKT activity.
- For endoderm work, confirm the result with morphology and markers such as SOX17 and FOXA2, and check that the cells can progress to the intended downstream lineage.
Protein Specifications
| Target | Activin A |
|---|---|
| Alternative names | INHBA |
| Species | Human |
| Expression system | HEK293 human cells |
| Structure | Disulfide-linked homodimer |
| Protein family | TGF-β superfamily |
| Gene symbol | INHBA |
| UniProt | P08476 |
| Tag | Tag-free |
| Animal origin | Animal-free / xeno-free manufacturing format |
| Molecular weight | Approximately 25 kDa. Refer to the lot-specific Certificate of Analysis (CoA) and SDS-PAGE profile for lot data. |
| Purity | >95% by SDS-PAGE |
| Endotoxin level | <0.5 EU/µg |
| Formulation | Lyophilized, carrier-protein free |
| Form | Lyophilized |
| Biological activity | Inhibition of murine MPC-11 plasmacytoma cell proliferation |
| EC50 | 6.68–10.02 ng/mL |
| Applications | Stem Cell Differentiation, Stem Cell Culture, 3D cell culture, Cell Reprogramming, Immunotherapy |
Biological Activity & Quality Control
Biological activity is measured by inhibition of murine MPC-11 plasmacytoma cell proliferation. The typical EC50 is 6.68–10.02 ng/mL. Each lot is tested for purity, endotoxin and biological activity before release.
Lot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.
Reconstitution
- Briefly centrifuge the vial before opening.
- Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.
- Mix gently and avoid aggressive vortexing.
- Prepare single-use aliquots under sterile conditions.
- Avoid repeated freeze–thaw cycles.
Storage & Shipping
| Storage | As supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles. |
|---|---|
| Shipping | Please contact us to confirm shipping conditions for this product. |
Safety & Handling
Handle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.
For research use only. Not for diagnostic or therapeutic use.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Peng F, et al. (2025) Chemical reprogramming of human blood cells to pluripotent stem cells. Cell Stem Cell 32:1192-1199.e11. 10.1016/j.stem.2025.07.003
Wang S, et al. (2024) Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell 187:6152-6164.e18. 10.1016/j.cell.2024.09.004
Lv Y, et al. (2023) The efficient generation of functional human hepatocytes from chemically induced pluripotent stem cells. Cell Prolif 57:e13540. 10.1111/cpr.13540
Guan J, et al. (2022) Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605:325-331. 10.1038/s41586-022-04593-5
Liu B, et al. (2021) Chemically defined and xeno-free culture condition for human extended pluripotent stem cells. Nat Commun 12:3017. 10.1038/s41467-021-23320-8
Lai W, et al. (2021) Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors. Stem Cell Reports 16:1697-1704. 10.1016/j.stemcr.2021.06.005
Yan P, et al. (2020) Genome-wide R-loop Landscapes during Cell Differentiation and Reprogramming. Cell Rep 32:107870. 10.1016/j.celrep.2020.107870
Xiang C, et al. (2019) Long-term functional maintenance of primary human hepatocytes in vitro. Science 364:399-402. 10.1126/science.aau7307